Tildrakizumab efficacy and drug survival by metabolic syndrome status in psoriasis: Post hoc analysis of 2 phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)
2019 ◽
Vol 81
(4)
◽
pp. AB441
Keyword(s):
Phase 3
◽
2019 ◽
Vol 81
(4)
◽
pp. AB446
2020 ◽
Vol 83
(6)
◽
pp. AB51
2020 ◽
Vol 83
(6)
◽
pp. AB164